Point72 Europe’s Bristol-Myers Squibb BMY Stock Holding History

Point72 Europe’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-218,813	Closed	-$12.4M	–	128
2024 Q4	$12.4M	Buy	218,813 +162,962	+292%	+$9.11M	0.72%	45
2024 Q3	$2.89M	Sell	55,851 -23,252	-29%	-$1.09M	0.18%	95
2024 Q2	$3.29M	Buy	+79,103	New	+$3.54M	0.27%	97
2024 Q1	–	Sell	-7,759	Closed	-$398K	–	152
2023 Q4	$398K	Buy	+7,759	New	+$407K	0.05%	174

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Europe's BMY Position: Q1 2025 in Review

Point72 Europe sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 218,813 shares — an estimated $12.4M sold.

Point72 Europe first reported a position in BMY in Q4 2023 and held it in 4 quarters. The position peaked at $12.4M in Q4 2024. 2,486 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Point72 Europe reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Point72 Europe sold 218,813 Bristol-Myers Squibb shares in Q1 2025, an estimated $12.4M.
Point72 Europe first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 4 quarters.
Point72 Europe's Bristol-Myers Squibb position peaked at $12.4M in Q4 2024.
2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Point72 Europe's 13F filing for Q1 2025, filed 15 May 2025.